Titre
Api m 6: a new bee venom allergen
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Kettner, A.
Auteure/Auteur
Hughes, G. J.
Auteure/Auteur
Frutiger, S.
Auteure/Auteur
Astori, M.
Auteure/Auteur
Roggero, M.
Auteure/Auteur
Spertini, F.
Auteure/Auteur
Corradin, G.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
0091-6749
Statut éditorial
Publié
Date de publication
2001-05
Volume
107
Numéro
5
Première page
914
Dernière page/numéro d’article
20
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: May
Research Support, Non-U.S. Gov't --- Old month value: May
Résumé
BACKGROUND: Characterization of the primary structure of allergens is a prerequisite for the design of new diagnostic and therapeutic tools for allergic diseases. OBJECTIVE: The purpose of this study was the identification and characterization of a low-molecular-weight, IgE-binding, bee venom (BV) allergen. METHODS: BV proteins were separated by using size exclusion chromatography and HPLC. IgE antibody binding to purified proteins was analyzed by means of immunoblotting, and T-cell response was analyzed by means of proliferation assay. Amino acid sequence was determined with 2 approaches, namely Edman degradation and carboxy terminal analysis with mass spectrometry. RESULTS: Api m 6, which migrated as an 8-kd band in SDS-PAGE, was frequently (42%) recognized by IgE from BV-hypersensitive patients. In addition, PBMCs from BV-hypersensitive patients, as well as from a normal control subject, proliferated in response to this allergen. Api m 6 exists as 4 isoforms of 7190, 7400, 7598, and 7808 d, respectively. Amino acid sequences obtained from HPLC-purified preparations revealed that the isoforms were constituted of a common central core of 67 residues, only differing in the amino- and carboxy-terminal ends. Api m 6 showed no significant sequence homology with known proteins. CONCLUSIONS: We have identified and sequenced a new BV allergen that elicits a strong IgE and T-cell response in a large number of BV-hypersensitive patients. Api m 6 should be considered in the diagnostic and therapeutic approach of BV immunotherapy on the basis of peptides or recombinant proteins.
Sujets
PID Serval
serval:BIB_A96274CCCC85
PMID
Date de création
2008-01-24T13:55:16.760Z
Date de création dans IRIS
2025-05-21T00:18:20Z